Oxford BioMedica Profit Margin 2021-2020 | OXBDF

Current and historical gross margin, operating margin and net profit margin for Oxford BioMedica (OXBDF) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Oxford BioMedica net profit margin as of December 31, 2020 is 0%.
Oxford BioMedica Annual Profit Margins
Oxford BioMedica Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.045B $0.113B
Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75